TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02153671

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A(H5N1) inactivated influenza vaccine (IIV)
Description: Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A(H5N1) inactivated influenza vaccine (IIV)
Description: Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A(H5N2) live attenuated influenza vaccine (LAIV)
Description: Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
Study: NCT02654093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Raloxifene co-administration
Study: NCT02958462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample, hair follicle, and saliva collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo a bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo a skin punch biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal Swab
Description: Undergo a saliva or buccal swab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: Undergo clinical assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT01107743

Intervention type: DRUG
Intervention: Amlodipine/Atorvastatin
Description: Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily.
Study: NCT04227496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory disturbances
Description: A sound will be played from a portable device (smartphone) during movement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory disturbances
Description: A sound will be played from a portable device (smartphone) during movement
Study: NCT00308737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder
Description: Inhalation, 15U/30U

Intervention type: DRUG
Group type: OTHER
Intervention: Usual Care
Description: Subjects will receive antidiabetes treatment at the discretion of their physicians
Study: NCT03246243

Intervention type: DEVICE
Intervention: nfant feeding solution
Description: The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.

Intervention type: DEVICE
Intervention: nfant feeding solution
Description: The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.

Intervention type: DEVICE
Intervention: nfant feeding solution
Description: The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
Study: NCT01915433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wahls Paleo Plus
Description: The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wahls Diet
Description: The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
Study: NCT01880372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Same as Arm description
Study: NCT03826511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tiszasüly hot mud-pack therapy
Description: Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kolop mud-pack
Description: Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
Study: NCT04157465

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment strategy trial
Description: Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy trial
Description: Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures.
Study: NCT03577574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrobulbar anesthesia
Description: 2% lidocaine 4ml injected into retrobulbar space
Study: NCT04128904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description.
Study: NCT04711174

Intervention type: BEHAVIORAL
Intervention: LMA removal
Description: the timing when conducting LMA removal

Intervention type: BEHAVIORAL
Intervention: LMA removal
Description: the timing when conducting LMA removal

Intervention type: BEHAVIORAL
Intervention: LMA removal
Description: the timing when conducting LMA removal

Intervention type: BEHAVIORAL
Intervention: LMA removal
Description: the timing when conducting LMA removal
Study: NCT03993574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self- management program
Description: The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: All stroke patients being discharged from the acute hospital receive the following care:~1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~2. A stroke clinic appointment that is set to occur 90-days post discharge.~3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~4. Information on local support groups.~5. Referrals to start physical, occupational or speech therapy, if recommended by their physician.
Study: NCT01000532

Intervention type: DEVICE
Intervention: SIELLO JT/T
Description: Implantation of SIELLO and BPPU pacemaker leads
Study: NCT03577574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peribulbar anesthesia
Description: 2% lidocaine 4 to 8ml injected into peribulbar space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two step anesthesia
Description: conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
Study: NCT01000532

Intervention type: DEVICE
Intervention: Pacemaker therapy
Description: Pacemaker therapy

Intervention type: DEVICE
Intervention: BPPU JT/T
Description: Implantation of SIELLO and BPPU pacemaker leads
Study: NCT02964754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan for internal fixation
Description: In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional internal fixation
Description: In the control group, patients will undergo conventional internal fixation.
Study: NCT03070769

Intervention type: PROCEDURE
Intervention: Venous blood collection for biomarkers measurements
Description: Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).

Intervention type: PROCEDURE
Intervention: Venous blood collection for biomarkers measurements
Description: Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
Study: NCT04453072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interviews

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Receive iPhone with W8Loss2Go app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale Device
Description: Receive body scale and food scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text message
Study: NCT02380261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® Lid Wipes
Description: Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
Study: NCT01844180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2952 Matching Placebo
Study: NCT01805882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451
Study: NCT03596437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra High Frequency ultrasound system
Description: Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra High Frequency ultrasound system
Description: Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
Study: NCT01225822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 300 mg q.d BIBR 1048 capsule for 5-10 treatment period
Study: NCT00720174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02482636

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP/IPV/Hib vaccine
Description: Given at 2, 3 and 4 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP/IPV/Hib vaccine
Description: Given at 2, 3 and 4 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus vaccine
Description: Given at 2 and 3 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus vaccine
Description: Given at 2 and 3 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 4-component Meningococcal B vaccine
Description: Given at 2, 4 and 12 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 4-component Meningococcal B vaccine
Description: Given at 2, 4 and 12 months to Group 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal C/Hib vaccine (MenC/Hib vaccine)
Description: Given at 12 months to Group1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal C/Hib vaccine (MenC/Hib vaccine)
Description: Given at 12 months to Group1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles/Mumps/Rubella Vaccine (MMR vaccine)
Description: Given at 13 months to Groups 1 and 2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles/Mumps/Rubella Vaccine (MMR vaccine)
Description: Given at 13 months to Groups 1 and 2
Study: NCT03214289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
Study: NCT03585491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet Procedure
Description: Participants will undergo open or arthroscopic Latarjet procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart + Remplissage Procedure
Description: Participants will undergo arthroscopic stabilization.
Study: NCT00624715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: * High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
Study: NCT02221245

Intervention type: PROCEDURE
Intervention: Tumor Biopsy via Ultrasound Endoscopy
Description: The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
Study: NCT03862196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored text messages to improve retention in HIV care
Description: Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.